Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
Status:
Completed
Trial end date:
2017-11-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of
certolizumab pegol (CZP) treatment in children and adolescents with moderately to severely
active Crohn's disease. Secondarily, to assess the long-term efficacy, pharmacokinetics (PK),
and immunogenicity of CZP treatment in children and adolescents with moderately to severely
active Crohn's disease.